CytoDyn Inc (OTCMKTS:CYDY), a late-stage biotechnology company, said Wednesday that it has treated its first patient with its lead drug leronlimab (PRO 140), in its Phase 2 clinical trial for ...
CytoDyn Inc (OTCMKTS:CYDY) said Wednesday that it has received approval from the Institutional Review Board for its drug leronlimab to be given to patients with triple-negative breast cancer (TNBC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results